Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
21st Century Therapeutics Inc
Amprologix Ltd
CrystalGenomics Inc
Debiopharm Intertiol SA
Destiny Pharma Plc
Lysimmune BioScience
Roivant Sciences Ltd
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Wockhardt Ltd
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-281 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-549 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epidermicin NI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LI-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit crtN for Staphylococcus aureus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Gram Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for MRSA and VRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Methionine tR Ligase for Gram Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Oxacillise for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tobacase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International SA, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Roivant Sciences Ltd, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H1 2020
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H1 2020